Olio Labs logo

Olio Labs

Emerging

SF AI drug discovery company identifying multi-protein combination therapeutics 4x faster at 90% lower cost; YC S23 $4.5M Boom Capital Series A with in vivo/vitro results competing with Recursion for combination therapy AI.

26
AI Score
Grade D↑ Trending
AI Visibility Score (Beta)
HealthcareWebsiteUpdated March 2026

Company Overview

About Olio Labs

Olio Labs is a San Francisco-based computational drug discovery company using AI and machine learning to identify multi-protein combination therapeutics for complex diseases — targeting biological pathways where single-target drugs fail because the disease involves multiple protein interactions simultaneously. Founded in 2023 and backed by Y Combinator (S23) with $5 million raised including a $4.5 million Series A led by Boom Capital and Overwater Ventures in March 2025, Olio Labs' combination therapeutics platform has demonstrated in vivo and in vitro superiority over existing market drugs, with a discovery process claimed to be 4x faster and 90% lower cost than traditional drug development approaches.

Business Model & Competitive Advantage

Olio Labs' multi-protein targeting approach addresses a fundamental limitation in drug development: most diseases — particularly cancer, autoimmune disorders, and neurological conditions — are driven by dysregulation across multiple protein pathways simultaneously. Single-target drugs (kinase inhibitors, checkpoint inhibitors) achieve partial response but face resistance as tumor cells activate compensatory pathways. Olio Labs' AI platform models protein interaction networks to identify combination therapies — selecting multiple agents that simultaneously target complementary pathway vulnerabilities — predicting synergistic drug combinations that human researchers cannot systematically explore across the combinatorial space of available compounds.

Competitive Landscape 2025–2026

In 2025, Olio Labs competes in the AI drug discovery and combination therapeutics market with Recursion Pharmaceuticals (NASDAQ: RXRX, large-scale phenomics and ML drug discovery), Insilico Medicine (AI generative drug design), and Relay Therapeutics (NASDAQ: RLAY, protein motion-based drug design) for AI-powered drug discovery positioning. The combination therapeutics field has validated market analogs — Pfizer's KRAS G12C inhibitor combination trials and cancer immunotherapy combinations have demonstrated that multi-agent oncology regimens outperform monotherapy. Olio Labs' YC-backing places it in the computational biotech community intersecting AI and drug discovery. The 2025 strategy focuses on identifying lead combination candidates for clinical development partnerships with pharmaceutical companies, generating additional preclinical proof-of-concept data, and raising Series B funding to advance the most promising combinations into IND-enabling studies.

Founded
2023
Curated content • Fact-checked and verified

Recent Activity

View all →

Key Differentiators

Emerging Innovator

Olio Labs is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

26
↑ Trending

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Browser Use logo

Browser Use

Developer Tools
B2bDeveloper ToolsPlatformSaasStartup

Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom

athenahealth logo

athenahealth

Healthcare
B2bCloud NativeEnterpriseErpHealthtechNorth AmericaSaas

athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on

Veeva Systems logo

Veeva Systems

Healthcare Tech
B2bHealthtechSaasPublic

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv

Oracle Health logo

Oracle Health

Healthcare
HealthtechNorth AmericaB2b

Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

Revvity logo

Revvity

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid

Compare Olio Labs with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Olio Labs

Claim This Profile

Are you from Olio Labs? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Olio Labs Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Olio Labs vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →